Olaf Stüve mainly investigates Multiple sclerosis, Immunology, Internal medicine, Natalizumab and Disease. His studies deal with areas such as Clinical trial, Pathology, Central nervous system disease, Inflammation and Central nervous system as well as Multiple sclerosis. His Central nervous system disease research incorporates elements of JC virus, Antibody and Lymphocyte.
His Internal medicine research includes elements of Interferon and Surgery. Monoclonal and Oncology is closely connected to Progressive multifocal leukoencephalopathy in his research, which is encompassed under the umbrella topic of Natalizumab. Olaf Stüve has included themes like Differential diagnosis, Observational study, Physical therapy and Stroke in his Disease study.
Multiple sclerosis, Immunology, Internal medicine, Natalizumab and Disease are his primary areas of study. He has researched Multiple sclerosis in several fields, including Clinical trial, Rituximab and Intensive care medicine. His study in Immune system, T cell, Antigen, Pathogenesis and Antibody falls within the category of Immunology.
His Internal medicine research incorporates themes from Endocrinology, Surgery, Oncology and Pharmacology. The concepts of his Natalizumab study are interwoven with issues in JC virus, Expanded Disability Status Scale, Alemtuzumab, Fingolimod and Glatiramer acetate. His studies in Disease integrate themes in fields like Young adult, Physical therapy and Neurology.
His scientific interests lie mostly in Multiple sclerosis, Internal medicine, Immunology, Experimental autoimmune encephalomyelitis and Natalizumab. The Multiple sclerosis study combines topics in areas such as Disease activity, Ocrelizumab, Clinical trial and Pharmacology. The various areas that Olaf Stüve examines in his Internal medicine study include Gastroenterology and Oncology.
His Experimental autoimmune encephalomyelitis research is multidisciplinary, relying on both Molecular biology, T cell, Adoptive cell transfer and Autoimmunity. His Natalizumab study combines topics from a wide range of disciplines, such as Immunosuppression, Progressive multifocal leukoencephalopathy and Intensive care medicine. His biological study spans a wide range of topics, including Lumbar puncture, CD3, Antigen and Pathology.
His primary areas of study are Multiple sclerosis, Internal medicine, Clinical trial, Monoclonal antibody and B cell. His Multiple sclerosis study combines topics in areas such as Neurodegeneration, Ocrelizumab, Autoimmunity, Neuroscience and CD20. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
His research integrates issues of Intervention, Treatment options, Placebo and Intensive care medicine in his study of Clinical trial. Olaf Stüve works mostly in the field of Monoclonal antibody, limiting it down to topics relating to Adverse effect and, in certain cases, Phases of clinical research and Antibody. His Rituximab study is concerned with the field of Immunology as a whole.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Sawsan Youssef;Olaf Stüve;Juan C. Patarroyo;Pedro J. Ruiz;Pedro J. Ruiz.
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
Martin S Weber;Thomas Prod'homme;Sawsan Youssef;Shannon E Dunn.
Nature Medicine (2007)
Immune surveillance in multiple sclerosis patients treated with natalizumab
Olaf Stüve;Olaf Stüve;Christina M Marra;Keith R Jerome;Keith R Jerome;Keith R Jerome;Linda Cook;Linda Cook;Linda Cook.
Annals of Neurology (2006)
Interferon beta in the treatment of multiple sclerosis Mechanisms of action
V. Wee Yong;Sophie Chabot;Olaf Stuve;Gary Williams.
Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
Olaf Stüve;Nora P. Dooley;Joon H. Uhm;Jack P. Antel.
Annals of Neurology (1996)
Acute disseminated encephalomyelitis: an update.
Til Menge;Bernhard Hemmer;Stefan Nessler;Heinz Wiendl.
JAMA Neurology (2005)
The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
Ruth Ann M Marrie;Stephen Reingold;Jeffrey A Cohen;Olaf Stuve.
Multiple Sclerosis Journal (2015)
Factors that influence adherence with disease-modifying therapy in MS.
Katherine Treadaway;Gary Cutter;Amber Salter;Sharon Lynch.
Journal of Neurology (2009)
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
Ruth Ann M Marrie;Jeffrey A Cohen;Olaf Stuve;Maria Trojano.
Multiple Sclerosis Journal (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: